国药控股(01099.HK)中期纯利增长6.33%至29.75亿元
格隆汇8月26日丨国药控股(01099.HK)公布,截至2019年6月30日止六个月,实现收入2016.65亿元人民币(单位下同),同比增长23.36%;毛利174.85亿元,同比增长20.9%;归属于母公司持有者本期溢利29.75亿元,同比增长6.33%;基本每股盈利1.00元。
报告期内,集团零售业务继续取得较快增长,销售收入达到88.42亿元,较去年同期上升24.51%,截至2019年6月30日,公司附属公司国药控股国大药房有限公司的门店覆盖全国19个省、直辖市和自治区,拥有4,593家零售药店,规模继续保持行业领先。集团的专业药房门店已经达到1,009家,网络覆盖全国30个省、直辖市和自治区。
据悉,2019年上半年集团医疗器械业务高速增长,销售收入达到290.25亿元,较去年同期上升35.96%,为本集团的收入和利润都带来了重要贡献。
医药分销分部方面,报告期间集团医药分销收入为1647亿元,较截至2018年6月30日止六个月增加22.22%,占集团总收入比例为80.38%,其增长主要是由于集团医药分销业务发展势态良好及分销网络进一步扩展。
其他业务分部报告期间集团其他业务收入为23.3亿元,较截至2018年6月30日止六个月增加11.65%,主要是由于化学试剂、医药制造业务收入上升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.